Reta GLP-1 Triple Agonist

Description

Reta GLP-1 is an investigational, once-weekly injectable medication designed for weight loss and obesity management, developed by Eli Lilly. Known as a “triple agonist” or “triple G” (GLP-1, GIP, and glucagon receptor agonist), it mimics three metabolic hormones to suppress appetite, improve metabolism, and increase calorie burn, with studies showing average weight loss.

FREE Reconstitution Calculator For Research: https://onlinepeptidecalculator.com/

For more in depth information: https://pubchem.ncbi.nlm.nih.gov/compound/171390338